You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Around the Region

Latest studies support Tysabri

Biogen Idec Inc.’s multiple sclerosis drug Tysabri performed well in studies that compared it to other treatments on the market, according to the Weston biotechnology company and its Irish partner in Tysabri, Elan PLC.

In particular, the results showed patients taking the drug who contract a rare brain disease — called progressive multifocal leukoencephalopathy — have a much better chance of recovering if the condition is detected earlier.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week